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Associations Between Measures of Sarcopenic Obesity and Risk of
Cardiovascular Disease and Mortality: A Cohort Study and Mendelian
Randomization Analysis Using the UK Biobank
Ruth E. Farmer, PhD;* Rohini Mathur, PhD;* A. Floriaan Schmidt, PhD; Krishnan Bhaskaran, PhD; Ghazaleh Fatemifar, PhD;
Sophie V. Eastwood, MSc, MBChB; Chris Finan, PhD; Spiros Denaxas, PhD; Liam Smeeth, FRCGP, PhD; Nish Chaturvedi, PhD
Background-—The “healthy obese” hypothesis suggests the risks associated with excess adiposity are reduced in those with
higher muscle quality (mass/strength). Alternative possibilities include loss of muscle quality as people become unwell (reverse
causality) or unmeasured confounding.
Methods and Results-—We conducted a cohort study using the UK Biobank (n=452 931). Baseline body mass index (BMI) was
used to quantify adiposity and handgrip strength (HGS) used for muscle quality. Outcomes were fatal and non-fatal cardiovascular
disease, and mortality. As a secondary analysis we used waist-hip-ratio or fat mass percentage instead of BMI, and skeletal muscle
mass index instead of HGS. In a subsample, we used gene scores for BMI, waist-hip-ratio and HGS in a Mendelian randomization
(MR). BMI deﬁned obesity was associated with an increased risk of all outcomes (hazard ratio [HR] range 1.10–1.82). Low HGS was
associated with increased risks of cardiovascular and all-cause mortality (HR range 1.39–1.72). HRs for the association between
low HGS and cardiovascular disease events were smaller (HR range 1.05–1.09). There was no suggestion of an interaction between
HGS and BMI to support the healthy obese hypothesis. Results using other adiposity metrics were similar. There was no evidence
of an association between skeletal muscle mass index and any outcome. Factorial Mendelian randomization conﬁrmed no evidence
for an interaction. Low genetically predicted HGS was associated with an increased risk of mortality (HR range 1.08–1.19).
Conclusions-—Our analyses do not support the healthy obese concept, with no evidence that the adverse effect of obesity on
outcomes was reduced by improved muscle quality. Lower HGS was associated with increased risks of mortality in both
observational and MR analyses, suggesting reverse causality may not be the sole explanation. ( J Am Heart Assoc. 2019;8:
e011638. DOI: 10.1161/JAHA.118.011638.)
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T he existence of a “healthy obese” phenotype, whereby asubgroup of individuals overcome the excess risk of
cardiovascular disease (CVD) and overall mortality associated
with obesity, remains debated. Proposed explanations for this
paradox include: (1) a favorable metabolic proﬁle, which has
been widely studied1: and (2) the co-occurrence of higher
muscle mass or strength. Sarcopenia (the age-related loss of
muscle mass and strength), is also associated with adverse
outcomes.2–4 Whether the effects of sarcopenia and obesity
are cumulative, or whether an interaction exists is unclear. A
recent review of prospective studies including 35 287
participants reported that individuals with both excess fat
and sarcopenia (sarcopenic obesity) had a 24% higher risk of
all-cause mortality compared with individuals with sarcopenia
alone or obesity alone, though conﬁdence limits were wide
(95% CI 12%–37%).5 The optimal measure of sarcopenia
(muscle mass versus muscle quality) for event prediction
remains contested.6 The optimal choice of obesity measure,
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whether central, (such as waist-hip-ratio [WHR]), or general
(speciﬁcally body mass index [BMI]) is also unclear.7–11
Concerns of reverse causality between obesity and outcomes,
particularly mortality, remain. For example, excess mortality in
those who have both lost weight and developed sarcopenia as
a consequence of disease may drive the appearance of a
protective effect of obesity.
We utilized UK Biobank (UKB) to determine the association
between sarcopenia, obesity and their interaction with CVD
events and mortality. We examined effect modiﬁcation by pre-
existing CVD and examined evidence for non-linearity of these
associations. As a secondary aim, we investigated the impact
of using different metrics for adiposity and muscle quality.
Mendelian randomization (MR) was used as a further casual
inference method to explore the relationship between genetic
instruments (and their interactions) for obesity and sarcope-
nia and CVD outcomes. Under certain assumptions, given that
genetic variation is determined at conception, such associa-
tions are robust to both confounding and reverse causation.12
Methods
Study Population
The data that support the ﬁndings of this study are available
to veriﬁed researchers upon application to the UKB in
accordance with their access procedures (http://www.ukb
iobank.ac.uk). The UKB cohort13,14 recruited 502,641 men
and women aged 40 and 69 years between 2006 and 2010
from primary care practices, spanning England, Scotland, and
Wales. Participants underwent a baseline assessment captur-
ing sociodemographic and lifestyle factors, and health status,
including several measures of adiposity, muscle mass and
muscle strength. Validated genotyping data were available
from the initial release of genetic data for a random sample of
150 000 participants. White European participants from this
sample with both phenotype and genotyping data passing
quality control were eligible for MR analysis. UKB genotyping
and imputation documentation are available at http://www.
ukbiobank.ac.uk/scientists-3/genetic-data/. Longitudinal fol-
low-up for health-related outcomes and mortality was avail-
able for all participants via linked secondary care records and
death registrations via the ofﬁce for national statistics.
This study had local approval from the UKB (project
number 21893) and institutional approval from the London
School of Hygiene & Tropical Medicine (application 15770). All
participants provided informed consent at the time of
recruitment to the UKB.
Observed Phenotypes
Body mass index and grip strength
General obesity was deﬁned using BMI, calculated with weight
and height measurements taken at the baseline assessment.
Muscle quality was deﬁned as isometric handgrip strength (HGS),
from the dominant hand using a Jamar dynamometer.15–17
We created binary variables for presence or absence of
obesity or sarcopenia. The BMI cut-off was >30 kg/m2.
Sarcopenia was dichotomized using HGS cut-offs at <30 kg
for men and <20 kg for women.18
A composite of 4 mutually exclusive categories of body
composition was generated. These were “optimal body compo-
sition” (ie, non-obese and non-sarcopenic), “obese non-sarcope-
nic,” “sarcopenic non-obese,” and “sarcopenic obesity.”
We further categorized each continuous exposure into
quintiles to examine non-linear associations between obesity
and sarcopenia. The studied population equated to the
following cut points: BMI: 23.55, 25.72, 27.85, and
30.82 kg/m2; HGS: 22, 28, 34, and 42 kg.
Outcome Variables
Our primary outcomes of interest were ﬁrst CVD event (fatal or
non-fatal) after cohort entry, CVD mortality and all-cause
mortality. CVD events were identiﬁed from linked hospital
inpatient data using International Classiﬁcation of Diseases,
TenthModiﬁcation (ICD-10) codes (in any diagnostic position) of
I00-I99 (excluding I10–I15) and Q20 to Q28 (https://
www.ucl.ac.uk/health-informatics/caliber).19 Deaths were
identiﬁed from linked death registration data if the relevant
codes appeared anywhere in the record. Events were identiﬁed
from baseline to March 31, 2015 (administrative end of
complete linkage follow-up).
Covariates
Ethnicity was self-reported at the nurse-validated baseline
assessment. Self-report of diabetes mellitus status at baseline
Clinical Perspective
What Is New?
• In a large sample of UK adults, greater muscle quality,
quantiﬁed by both directly measured and genetically
predicted hand-grip strength, was estimated to reduce
cardiovascular and all-cause mortality risk.
• There was no evidence for “healthy obesity:” higher body
mass index was associated with higher cardiovascular and
all-cause mortality risk, and this was not attenuated in
people with better muscle quality.
What Are the Clinical Implications?
• Grip strength may be a useful prognostic indicator for
cardiovascular and all-cause mortality risk, regardless of
adiposity level.
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was adjudicated using the UKB algorithm.20 Deprivation was
deﬁned using the Townsend score, categorized into quin-
tiles.21 Data on tobacco and alcohol consumption, and
physical activity were obtained via the baseline touchscreen
questionnaire. Smoking status was categorized into 6 groups:
never smoker, ex-smoker, 1 to 9, 10 to 19, 20 to 29, and ≥30
cigarettes per day. Frequency of alcohol intake at baseline
was grouped into the following categories: never, special
occasions only, once or twice a month, once or twice a week,
and (almost) daily. Number of days a week where participants
undertook >10 minutes of moderate physical activity and
vigorous physical activity were treated as separate categorical
variables. We chose not to include additional data on number
of minutes per session to create composite variable for
metabolic hours per week as this greatly reduced the sample
size. History of CVD at baseline was ascertained using both
baseline interview and linked secondary care data. Use of lipid
lowering and anti-hypertensive medications was reported and
checked by a nurse, and blood pressure was measured. Data
on high-density lipoprotein, low-density lipoprotein, and total
cholesterol were not available.
Statistical Analysis
Separate, cause-speciﬁc Cox proportional hazard models
(whereby deaths from other causes were censored), were
ﬁtted to estimate the association with each time to event
outcome. Participants were considered at risk from
12 months after their baseline interview date to exclude
events that could not be plausibly affected by baseline
measures of body composition. In other words, we wanted to
ensure that the results were not affected by reverse causality.
This meant that participants experiencing the event of interest
in the ﬁrst 12 months were not included in the analysis.
Follow-up time either: (1) ended at the ﬁrst occurrence of the
outcome; or (2) was censored at the end of the follow-up
period or death (where death was not the outcome).
Risk of CVD events, CVD mortality, and all-cause mortality
was compared across the 4 categories of body composition,
stratiﬁed by history of CVD at baseline, with “optimal body
composition” as the reference category. All models were
adjusted for the following known risk factors for CVD/
mortality which are also likely to impact body composition/
strength: age (linear term), sex, smoking status, ethnic group,
deprivation, diabetes mellitus status, alcohol consumption,
and moderate physical activity at baseline. Vigorous physical
activity was omitted from the models, as it was not found to
improve model ﬁt or change any estimates of interest once
moderate physical activity was included. We did not adjust for
use of lipid lowering medications at baseline, as use of statins
has been shown to not be a good proxy for current cholesterol
and is more indicative of health seeking behavior and vascular
risk;22 for which we could better adjust for using variables for
smoking, alcohol, and physical activity. While blood pressure
and cholesterol are strong predictors of CVD incidence, it is
likely that these 2 variables are at least partly on the causal
pathway between body composition and the outcomes or
share common risk factors with our main exposures, making
adjustment for them as “confounders” inappropriate and
potentially misleading.23
Tests for interactions between BMI and HGS were
performed using Wald tests.
Participants with missing data for any model variable
(<11%) were excluded (Figure 1). Missing values for covari-
ates such as smoking, alcohol, and physical activity were
likely missing not at random, so multiple imputation was not
appropriate. We used a complete case analysis under the
assumption that, conditional on model covariates, missing-
ness was independent of the outcome.24
Sensitivity Analysis
To further assess possible reverse causality, all analyses using
the 4-level variable for body composition were re-run exclud-
ing the ﬁrst 2, 3, then 4 years of follow-up. Secondly, since it
is possible that the inclusion of less severe CVD events in the
composite CVD outcome may reduce any association or
interaction, we also looked at coronary heart disease (CHD)
(ICD-10 codes I20–25, I46, I47 and I49) as an additional
outcome.
Secondary Analyses
To investigate whether other measures of muscle quality or
adiposity may provide differing results we repeated the
primary analysis using skeletal muscle mass index (SMMI) in
place of hand-grip strength and replacing BMI with waist-hip-
ratio (WHR) and then with fat mass (%). SMMI was calculated
from the bioelectrical impedance measures using the Janssen
et al equation, then taking the bottom 40% of the distribution
as the deﬁnition of sarcopenia.25–27 The cut-off for obesity for
WHR was deﬁned as ≥0.95 for men and ≥0.80 for women. Fat
mass percentage does not have a well-deﬁned cut-off in terms
of obesity, therefore we used this metric to compare
differences between quintiles only.
Mendelian Randomization
After excluding potentially related samples, variants for BMI,
WHR, and HGS, were screened on Hardy-Weinberg equilibrium
(threshold log10 (P value) ≤19106), and (where relevant)
imputation quality (Table S1). We used previously identiﬁed
independent variants to calculate weighted genetic instru-
ments for BMI, WHR, and HGS.28–31 Some of the identiﬁed
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variants did not pass quality control in our data and were
therefore excluded from the genetic score (Tables S2 through
S4). Weights were derived based on variant to phenotype
associations. Two sets of weights were calculated, using
internal and then external data28–30 to prevent weak instru-
ment bias. Genetic score (GS) instrument strength was
quantiﬁed using the F-statistic of a linear regression model
relating the GS to the intermediate phenotypes, with a
statistic of ≥10 indicating the instrument had sufﬁcient
strength. Variants for HGS were taken from a previous study29
using the UKB as there are no published independent
genome-wide association studies. These weighted GS were
subsequently associated with outcomes using Cox propor-
tional hazard models, allowing for an interaction between BMI
and HGS using a factorial MR (FMR) design.32 The FMR
explored interactions by ﬁrst categorizing the GS into high
versus low (cut at the median), and combining these in a 4-
level categorical variable, and then by entering the 2 scores as
continuous linear terms with an interaction. In line with the
observational analysis, we then repeated this using WHR
instead of BMI as a secondary analysis, and also considered
CHD events and mortality in a sensitivity analysis. Interaction
P values were obtained from likelihood ratio tests. To
investigate pleiotropy, we also examined associations
between individual variants used to develop the GS for each
phenotype and other measured risk factors for CVD and
mortality.
Multiple Testing
Throughout our analyses, we made no adjustment for multiple
testing. Provided results are appropriately interpreted, the
adjustment in unnecessary, particularly when the multiple
outcomes/exposures being tested are correlated as is the
case here.33 We aimed to focus on the overall pattern of
results, and used the CIs to provide the range of effect
estimates for which our data were compatible rather than
looking at whether a particular interval included or excluded
the null. By the same argument, for the statistical tests of
interaction, we also considered overall pattern of results
rather than focusing on individual P values.
Results
A total of 452 931 participants had complete data on BMI,
HGS, and all covariates (Figure 1). Baseline characteristics
stratiﬁed by body composition (according to BMI and HGS)
are shown in Table 1. Twenty percent of participants had
obesity but not sarcopenia, 11% had sarcopenia but not
obesity, and 4% had both (sarcopenic obesity). Mean follow-up
time after excluding the ﬁrst 12 months was 5.1 years.
During follow-up, there were 30 842 fatal and non-fatal CVD
events, and 11 336 deaths (3273 CVD).
Observational Analysis
In participants with no history of CVD, BMI-deﬁned obesity in
the absence of sarcopenia was associated with an increased
risk of CVD events (adjusted hazard ratio [HR], 1.29 [1.24–
1.35]). The analogous estimate for those with prior CVD was
1.23 (1.16–1.30) (Figure 2). Obesity in the absence of
sarcopenia was also associated with an increased risk of
mortality (Figure 2).
Sarcopenia without obesity had a more modest association
with risk of CVD events, relative to optimal body composition,
regardless of prior CVD (HR range, 1.04–1.09). Estimated
Figure 1. Flowchart of numbers included in study for observational analyses and Mendelian random-
ization. BMI indicates body mass index; HGS, hand-grip strength; QC, quality control; WHR, waist-hip-ratio.
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Table 1. Baseline Characteristics of 452 931 Individuals in the UKB With BMI and Hand-Grip Strength Measures and Complete
Covariate Data, Stratiﬁed By Body Composition as Deﬁned By BMI and Hand-Grip Strength
Denominator
Optimal Obese Sarcopenic Sarcopenic Obese
296 567 (65%) 89 906 (20%) 48 250 (11%) 18 208 (4%)
Follow-up time (y) (median, IQR) 6.18 5.48–6.86 6.17 5.46–6.88 6.00 5.31–6.67 6.01 5.32–6.72
Death during follow-up, n (%) 6710 2.3% 2790 3.1% 1822 3.8% 827 4.5%
CVD death during follow up n (%) 1701 0.6% 991 1.1% 557 1.2% 308 1.7%
Any CVD event during follow-up, n (%) 17 082 5.8% 8135 9.1% 3759 7.8% 2314 12.7%
Mean age at baseline (SD) 55.9 8.2 56.2 7.9 59.5 7.3 59.4 7.1
Male, n (%) 140 302 47.3% 45 979 51.1% 13 820 28.6% 5467 30.0%
Ethnic group, n (%)
White 284 023 95.8% 85 297 94.9% 44 518 92.3% 16 826 92.4%
South Asian 3369 1.1% 869 1.0% 1657 3.4% 527 2.9%
African Caribbean 3495 1.2% 2237 2.5% 528 1.1% 420 2.3%
Other 5680 1.9% 1503 1.7% 1547 3.2% 435 2.4%
Townsend deprivation score (mean, SD) 1.6 2.9 1.0 3.2 1.2 3.1 0.4 3.4
Comorbidities, n (%)
Type 1 diabetes mellitus 827 0.3% 335 0.4% 229 0.5% 111 0.6%
Type 2 diabetes mellitus 7149 2.4% 8786 9.8% 2241 4.6% 2813 15.4%
History of CHD 11 599 3.9% 7061 7.9% 3077 6.4% 2146 11.8%
History of CVD (CHD, stroke, angina) 33 226 11.2% 15 140 16.8% 7585 15.7% 4321 23.7%
Smoking status, n (%)
Never smoker 208 804 70.4% 57 030 63.4% 34 242 71.0% 11 914 65.4%
Ex-smoker 65 794 22.2% 27 014 30.0% 10 341 21.4% 5144 28.3%
Current-smoker 21 969 7.4% 5862 6.5% 3667 7.6% 1150 6.3%
1 to 9 cigarettes per day 4760 1.6% 920 1.0% 790 1.6% 171 0.9%
10 to 19 cigarettes per day 9407 3.2% 2347 2.6% 1681 3.5% 473 2.6%
20 to 29 cigarettes per day 6274 2.1% 1920 2.1% 952 2.0% 378 2.1%
30+ cigarettes per day 1528 0.5% 675 0.8% 244 0.5% 128 0.7%
Alcohol consumption, n (%)
Never 18 696 6.3% 7650 8.5% 5638 11.7% 2895 15.9%
Special occasions only 27 608 9.3% 12 837 14.3% 6814 14.1% 3828 21.0%
Once or twice a month 30 881 10.4% 12 209 13.6% 5255 10.9% 2438 13.4%
Once or twice a week 76 936 25.9% 24 131 26.8% 12 034 24.9% 4312 23.7%
3 or 4 times a week 75 610 25.5% 18 285 20.3% 9637 20.0% 2637 14.5%
Almost daily 66 836 22.5% 14 794 16.5% 8872 18.4% 2098 11.5%
PA (median [IQR])
Days of moderate PA per week 4 [2,6] 3 [1,5] 4 [2,6] 3 [1,5]
Days of vigorous PA per week 2 [0,3] 1 [0,3] 1 [0,3] 0 [0,2]
Anthropometric/metabolic measures (mean, SD)
Systolic blood pressure 136.47 18.62 142.01 17.69 136.50 19.27 141.33 18.64
BMI, kg/m2 25.32 2.69 33.81 3.74 25.19 2.82 34.37 4.74
Whole body fat mass (%) 28.80 7.51 37.62 7.75 31.83 7.31 41.18 6.98
Waist-hip-ratio 0.85 0.08 0.92 0.09 0.85 0.08 0.91 0.09
Continued
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associations with mortality were larger (HR range, 1.39–1.72)
(Figure 2).
Sarcopenic obesity (deﬁned by HGS and BMI) was
associated with the highest risk of CVD events compared
with the other 3 categories of body composition, with no clear
differences between those with and without prior CVD. For
mortality outcomes, sarcopenic obesity individuals had esti-
mated risks consistent with sarcopenic non-obese individuals,
again with minimal differences by CVD history (Figure 2).
There was no clear evidence of an interaction between
sarcopenia and obesity for CVD events. The relative effects of
obesity appeared similar with and without the presence of
sarcopenia, and vice versa, with and without prior CVD
(Figure 2). Statistically, there was evidence of interactions
between sarcopenia and obesity formortality outcomes, but the
direction of this was suggestive of a reduced relative effect of
obesity in those who were sarcopenic. Further, the estimated
size of the interactions was not large in magnitude (Figure 2).
Table 1. Continued
Denominator
Optimal Obese Sarcopenic Sarcopenic Obese
296 567 (65%) 89 906 (20%) 48 250 (11%) 18 208 (4%)
Skeletal muscle mass index, kg/m2 7.63 1.39 8.65 1.50 6.96 1.30 7.98 1.49
Grip strength, kg 34.14 10.02 34.97 10.54 17.74 5.63 17.35 11.29
BMI indicates body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; IQR, interquartile range; PA, physical activity.
Figure 2. Estimated association between body composition and fatal/non-cardiovascular disease (CVD) events and cause-speciﬁc and all-
cause mortality. Obesity measured as body mass index >30, sarcopenia measured as HGS <30 kg men and <20 kg women.
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Risk of CVD events increased linearly by quintile of BMI,
but within BMI quintile, there was no clear pattern of an
association with HGS (Tables 2 and 3). In contrast, for the
mortality outcomes, there was less evidence of an association
with BMI quintile, but there was clear pattern of decreasing
risk with increasing HGS quintile. A “U” shaped association
was observed for the effect of BMI on CVD mortality and all-
cause mortality in the lowest quintile of HGS, particularly for
those with a prior history of CVD. In general, however, there
was little evidence of non-linearity (Tables 2 and 3). There was
no other strong suggestion that the effect of BMI differed by
HGS, or vice versa, as reﬂected in both the estimates of effect
and interaction P values.
Sensitivity Analyses
Extending the exclusion period at the beginning of follow-up
appeared to make minimal differences to the results
(Figure S1). Results for CHD events and mortality had
similar pattern to those for CVD events and mortality as a
whole, though in general effect sizes for the effect of
obesity were larger in magnitude (Figure S2 and Tables S5
and S6).
Secondary Analyses
The proportion of individuals with sarcopenic obesity at
baseline differed substantially for each of the 4 deﬁnitions;
varying from 2% using BMI and SMMI, to 17% using WHR and
SSMI (Table S7). Associations between sarcopenia as deﬁned
by SMMI and all outcomes were generally null compared with
those with normal body composition (Figure S3). Further,
there was no consistent evidence of an association between
SMMI quintiles and any outcome, regardless of BMI quintile
(Tables S8 and S9).
Using WHR instead of BMI gave similar results for all
analyses performed (Figure S4 and Tables S10 and S11).
Using fat mass quintiles gave a similar pattern of results as
BMI, though there was stronger evidence for an interaction
with HGS. However, this appeared to be driven by the same U-
shaped association observed for BMI at the lower HGS
quintiles. (Tables S12 and S13).
Table 2. Adjusted* Hazard Ratios (with 95% CI) of All-Cause and CVD Mortality, and Combined Fatal/Non-CVD Events By Quintiles
of BMI and HGS, in Patients With No Prior History of CVD
HGS Quintile (kg)
43 to 90 35 to 42 29 to 34 23 to 28 0 to 22
P Value for
Interaction
BMI quintile (kg/m2)
All-cause mortality
12 to 23 1 (ref) 1.37 (1.12–1.69) 1.52 (1.23–1.87) 1.84 (1.50–2.26) 2.23 (1.82–2.73) 0.169
23 to 26 0.92 (0.75–1.15) 1.17 (0.96–1.44) 1.63 (1.33–2.00) 1.70 (1.38–2.09) 1.88 (1.53–2.31)
26 to 28 1.02 (0.83–1.24) 1.17 (0.96–1.42) 1.40 (1.14–1.72) 1.62 (1.31–2.00) 1.92 (1.56–2.37)
28 to 31 1.14 (0.94–1.39) 1.23 (1.01–1.49) 1.51 (1.23–1.85) 1.67 (1.35–2.06) 2.05 (1.67–2.52)
31 to 60 1.35 (1.10–1.65) 1.39 (1.14–1.70) 1.67 (1.36–2.05) 1.83 (1.49–2.26) 2.07 (1.69–2.53)
Fatal/non-fatal CVD
12 to 23 1 (ref) 0.92 (0.77–1.09) 1.06 (0.90–1.25) 1.03 (0.87–1.22) 0.96 (0.81–1.14) 0.376
23 to 26 0.98 (0.83–1.15) 1.03 (0.88–1.21) 1.06 (0.90–1.25) 1.06 (0.90–1.26) 1.08 (0.92–1.28)
26 to 28 1.11 (0.95–1.29) 1.13 (0.96–1.31) 1.10 (0.93–1.30) 1.14 (0.96–1.35) 1.11 (0.94–1.32)
28 to 31 1.15 (0.98–1.34) 1.19 (1.02–1.39) 1.22 (1.04–1.44) 1.18 (0.99–1.40) 1.34 (1.13–1.58)
31 to 60 1.51 (1.30–1.76) 1.31 (1.12–1.54) 1.60 (1.37–1.87) 1.48 (1.25–1.74) 1.49 (1.27–1.75)
Fatal CVD
12 to 23 1 (ref) 1.38 (0.90–2.12) 1.39 (0.88–2.18) 1.80 (1.14–2.83) 2.63 (1.71–4.06) 0.225
23 to 26 0.94 (0.60–1.47) 1.20 (0.79–1.83) 1.52 (0.98–2.35) 2.32 (1.50–3.59) 2.38 (1.53–3.70)
26 to 28 1.07 (0.71–1.64) 1.15 (0.76–1.74) 1.32 (0.85–2.05) 1.54 (0.96–2.46) 2.12 (1.35–3.34)
28 to 31 1.30 (0.87–1.96) 1.35 (0.90–2.03) 1.72 (1.13–2.63) 1.91 (1.22–3.00) 3.06 (2.00–4.70)
31 to 60 1.63 (1.08–2.45) 1.69 (1.13–2.54) 2.54 (1.69–3.82) 2.89 (1.89–4.42) 2.55 (1.66–3.92)
BMI indicates body mass index; CVD, cardiovascular disease; HGS, hand-grip strength.
*Adjusted for age, sex, ethnicity, and baseline measures of smoking, alcohol consumption, diabetes mellitus status, physical activity and deprivation.
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MR Analysis
A total of 111 348 participants contributed to MR (Figure 1).
The median genetically predicted values for BMI, WHR, and
HGS were 27.5 kg/m2, 0.88, and 32.2 kg, respectively
(Figure 3). The F statistics for the 3 scores were 2009, 500,
and 128 using external weights; and 2250, 569, and 137 with
internal weights for BMI, WHR, and HGS, respectively,
indicating that both internal and external genetic scores
(GS) were strong instruments.
The factorial analysis suggested no statistical evidence of
interaction between BMI and HGS (Figure 4). In general, there
was no clear evidence of an increased risk of fatal/non-fatal
CVD for any combination of genetic scores for BMI and HGS. All
HRs were close to 1 for both internal and externally weighted
GS (maximum HR: 1.04, minimum HR: 0.99). Broadly, low HGS
was estimated to increase the risk of mortality outcomes
compared with high HGS, irrespective of obesity category
(Figure 4), though the effect sizes were smaller than those from
the observational analysis. In participants with high HGS
scores, there was no evidence of any effect of BMI on CVD and
all-cause mortality (HRs 1.09 [0.91–1.30] and 0.96 [0.87–
1.06], respectively for externally weighted GS, and 0.99 [0.83–
1.18] and 0.98 [0.89–1.08] for internally weighted GS. This lack
of BMI effect was also observed in those with low HGS
(Figure 4).
Using internally weighted GS as continuous variables
instead of dichotomizing at the median, there remained no
evidence for an interaction between BMI and HGS for any of
the outcomes (Table 4). As with the dichotomized risk
scores, the estimated HRs per unit increase in BMI for all
outcomes from these models were estimated to small in
magnitude (HR range, 1.00–1.04) and all CIs included 1. This
was also true for the effect of grip strength on fatal/non-
fatal CVD (HR 1.02 [0.97–1.08]). However, each unit
increase in HGS was estimated to reduce the relative risk
of all-cause and CVD mortality by around 10% at the median
BMI score (HR 0.86 [0.79–0.94] and 0.88 [0.75–1.02],
respectively).
Results using genetic scores for WHR instead of BMI were
similar (Figure S5 and Table S14), as were results for CHD and
CHD mortality (Figure S6 and Table S14).
Table 3. Adjusted* Hazard Ratios (with 95% CI) of All-Cause and CVD Mortality, and Combined Fatal/Non-CVD Events By Quintiles
of BMI and HGS, in Patients With Prior History of CVD
HGS Quintile (kg)
43 to 90 35 to 42 29 to 34 23 to 28 0 to 22
P Value for
Interaction
BMI quintile (kg/m2)
All-cause mortality
12 to 23 1 (ref) 1.49 (0.95–2.32) 2.03 (1.31–3.13) 2.95 (1.92–4.53) 3.45 (2.27–5.24) 0.007
23 to 26 1.31 (0.84–2.04) 1.33 (0.87–2.03) 1.86 (1.22–2.85) 2.10 (1.35–3.25) 2.15 (1.39–3.32)
26 to 28 1.23 (0.81–1.89) 1.30 (0.86–1.96) 1.93 (1.28–2.92) 1.88 (1.21–2.91) 2.01 (1.31–3.09)
28 to 31 1.21 (0.80–1.83) 1.44 (0.96–2.16) 1.50 (0.99–2.26) 1.63 (1.05–2.51) 2.01 (1.32–3.07)
31 to 60 1.45 (0.96–2.18) 1.54 (1.03–2.29) 1.58 (1.05–2.37) 2.31 (1.53–3.48) 2.74 (1.82–4.10)
Fatal/non-fatal CVD
12 to 23 1 (ref) 1.06 (0.80–1.39) 1.26 (0.96–1.65) 1.14 (0.86–1.5) 1.25 (0.96–1.63) 0.070
23 to 26 1.11 (0.85–1.45) 1.33 (1.03–1.70) 1.29 (1.00–1.68) 1.19 (0.90–1.56) 1.26 (0.97–1.64)
26 to 28 1.29 (1.00–1.65) 1.31 (1.03–1.68) 1.29 (1.00–1.67) 1.36 (1.05–1.78) 1.30 (1.00–1.69)
28 to 31 1.24 (0.97–1.58) 1.32 (1.04–1.69) 1.21 (0.94–1.56) 1.3 (1.00–1.69) 1.47 (1.14–1.89)
31 to 60 1.66 (1.30–2.11) 1.42 (1.12–1.80) 1.68 (1.32–2.14) 1.59 (1.24–2.04) 1.79 (1.41–2.29)
Fatal CVD
12 to 23 1 (ref) 2.34 (1.02–5.33) 3.40 (1.51–7.65) 4.69 (2.07–10.61) 6.76 (3.06–14.93) 0.146
23 to 26 1.82 (0.79–4.18) 2.45 (1.11–5.39) 2.64 (1.18–5.93) 3.87 (1.71–8.74) 4.12 (1.82–9.29)
26 to 28 2.03 (0.91–4.51) 2.37 (1.09–5.15) 3.53 (1.62–7.69) 3.57 (1.59–8.02) 3.09 (1.36–7.02)
28 to 31 1.57 (0.71–3.49) 2.65 (1.23–5.71) 2.66 (1.22–5.81) 3.35 (1.51–7.45) 3.97 (1.79–8.77)
31 to 60 2.85 (1.32–6.16) 2.96 (1.38–6.34) 3.31 (1.54–7.13) 4.26 (1.96–9.26) 5.21 (2.41–11.28)
BMI indicates body mass index; CVD; cardiovascular disease; HGS, hand-grip strength.
*Adjusted for age, sex, ethnicity, and baseline measures of smoking, alcohol consumption, diabetes mellitus status, physical activity and deprivation.
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Assessment of Potential Pleiotropy
Three BMI variants were identiﬁed that were genome-wide
signiﬁcantly associated with systolic blood pressure (SBP), WHR,
and use of lipid-lowering drugs (Figure 5A). One WHR SNP was
found to also be associated with HGS. Although not reaching
genome-wide statistical signiﬁcance, many SNPs had relatively
large beta estimates for an association with SBP (Figure 5B).
Discussion
In a study of 450 000 UK adults, we found no evidence for a
healthy obesity phenotype in association with muscle
strength using observed phenotypes in a multivariable
regression or using Mendelian randomization approaches in
111 348 individuals with available genetic and phenotype
data. Increased BMI was linearly associated with increased
risk of both CVD events and mortality (CVD and all-cause) to a
similar degree. Greater muscle quality, as measured by HGS
or by variants acting as instrumental variables were estimated
to reduced CVD and all-cause mortality risk but showed less
association (both statistically and in magnitude) with fatal/
non-fatal CVD events. Our overall ﬁndings do not support a
“U” or “J” shaped association between adiposity and any
outcome; however, few participants were clinically under-
weight. There was no consistent evidence that the effect of
adiposity was modiﬁed by grip strength or skeletal muscle
mass, and vice-versa, suggesting that the negative effects of
obesity are not reduced in those with greater strength, or that
the observed reduction in risk of mortality with increasing
strength is not negated by excess adiposity.
Previous studies that have examined the joint effect of grip
strength and obesity are limited by small sample size and
potential for reverse causality.34,35 For the latter issue, our
ﬁndings were unchanged when we excluded events occurring
in the ﬁrst and subsequent 2, 3, and 4 years of follow-up, and
when stratiﬁed by prior history of CVD. UKB participants are
relatively young; relatively small numbers have pre-existing
disease or extreme anthropometric phenotypes,36 which
could explain this. Indeed, the proportion of clinically
underweight, at <1%, and obese, at 4%, was low, also making
it harder to detect non-linear associations if they exist.
From secondary analyses, our ﬁnding of similarity between
BMI and WHR in terms of subsequent risk is in line with a
recent comparative study of 4 UK-based cohorts.11 The
ﬁnding that muscle strength deﬁned by HGS appears to be of
greater prognostic value than muscle mass deﬁned by SMMI
adds to a growing body of evidence;.5,37
In contrast to a recent study also using the UKB,4 we found
no clear evidence of an effect of sarcopenia on incident or
recurring CVD events. However, the existing study used a
narrower deﬁnition of CVD which may explain the stronger
effects observed.
In our observational analysis, we found that sarcopenia
was strongly related to mortality, consistent with existing
observational evidence.3,4 Despite similar ﬁndings in those
with and without prior CVD suggesting that reverse causality
had little impact on ﬁndings, we cannot exclude the possibility
of some misclassiﬁcation of prior CVD because of undiag-
nosed disease at baseline. However, the number of undiag-
nosed individuals would have to be large to explain this fully.
31 32 33 34
HGS
26 28 30
BMI
86 88 90
WHR
Figure 3. Distributions of genetic risk scores for hand-grip
strength (HGS) (kg) (top), BMI (kg/m2) (middle) and waist-hip-ratio
(WHR) (bottom). BMI indicates body mass index; HGS, hand-grip
strength; WHR, waist-hip-ratio.
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Further, in contrast to a previous, smaller MR study,29 the
harmful effect of lower genetically predicted HGS on mortality
outcomes was replicated when using genetically predicted
HGS, most notably for all-cause mortality. This suggests it is
even less likely that the adverse effect of sarcopenia on
mortality is solely attributable to reverse causality.
Potential causal mechanisms for the observed association
between HGS and mortality outcomes include the effect of
skeletal muscle on exercise capacity, itself a strong predictor
of mortality, via maintenance of preload and cardiac output
during physical activity.38
The MR analysis also found no evidence of an interaction
between adiposity and HGS. In our observational analysis,
there was some suggestion of a protective effect of obesity in
sarcopenic individuals for mortality outcomes, which resulted
in some statistical evidence of interactions. This direction of
Figure 4. Relative hazard of fatal/non-fatal cardiovascular disease (CVD) events and cause speciﬁc and all-cause mortality according to
category of body composition as deﬁned by genetic scores estimated from both external in internal weights in a factorial Mendelian
randomization analysis.
Table 4. Results of MR Using Continuous Genetic Scores* With Interaction Between HGS and BMI
Outcome
HR Per Unit Increase in
HGS At the Median BMI
HR Per Unit Increase in
BMI at the Median HGS
Interaction
Term (HR)
Interaction
P Value
Fatal/non-fatal CVD 1.02 (0.97–1.08) 1.04 (1.00–1.07) 0.97 (0.89–1.05) 0.434
CVD mortality 0.88 (0.75–1.02) 1.03 (0.94–1.13) 1.12 (0.89–1.40) 0.344
All-cause mortality 0.86 (0.79–0.94) 1.00 (0.96–1.06) 1.08 (0.95–1.22) 0.239
BMI indicates body mass index; CVD, cardiovascular disease; HGS, hand-grip strength; HR, hazard ratio; WHR, waist-hip-ratio.
*Genetic risk score derived from internal weights.
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interaction is not consistent with the healthy obese hypoth-
esis and may be a consequence of un-measured confounding
by frailty.
A key strength of the study was the additional use of MR
analyses, an important tool in establishing causality. However,
the following issues deserve consideration. Given the sparsity
of GWAS data on HGS, SNP selection29 as well as estimation
utilized the same UKB sample, resulting in a degree of
selection bias (eg, inﬂated weights). This type of selection bias
decreases to zero as sample size increase.39 Given the size of
the UKB we expect this source of bias to have minimal
inﬂuence on presented results. Our results are also strength-
ened by the ﬁnding that using external weights for BMI, WHR,
and HGS showed similar results, and the F statistics for both
internal and external weights were large for all predicted
phenotypes.
An alternative explanation for our ﬁndings is that genes
that predict grip strength may also predict other phenotypes
associated with health status (pleiotropic effects). Because of
the focus on factorial MR, we were unable to use more robust
methods such as MR-egger that protect against bias because
of horizontal pleiotropy and acknowledge this may be a
limitation of our study. However, we were able to explore the
pleiotropy potential of the used variants by examining the
associations between the genetic risk scores and other CVD
risk factors. Here, we found only 3 genome-wide signiﬁcant
associations with potentially pleiotropic pathways such as
SBP and use of lipid-lowering drugs. However, these pathways
may well lie on the causal pathway between our exposures
(BMI, WHR, and HGS) and CVD, which does not bias or
invalidate our results (horizontal pleiotropy). Having said this,
there may exist alternative pleiotropic pathways that we were
unable to examine given the available data.
As expected, distributions of the genetic risk scores for
BMI, WHR, and HGS showed far less variation than the
observed phenotypes. Genetically predicted HGS ranged from
30 to 35 kg, BMI ranged from 27 to 31. This may explain the
lack of effect of observed genetic associations and small HR
estimates for BMI and WHR on any of the outcomes when
dichotomized at the median genetic score. This could also
contribute to the lack of interaction observed here. Further,
we cannot exclude the possibility that we were underpowered
to detect the interactions in this analysis given the smaller
effect sizes, though given our sample size we believe this
unlikely.
Our study is limited by mean follow-up period of 5 years,
limiting the number of incident events available for analysis.
Indeed, the number of deaths occurring in our sample
(11 336) was comparable with the number of deaths observed
in the 2016 meta-analysis (14 306), which had a far smaller
overall sample size. However, the previously mentioned
healthy participant bias may explain the overall lower event
rates and limited our ability to look at people with severe
obesity but should not bias associations between obesity and
outcomes.
A further limitation is that the lack of repeated measures of
obesity and sarcopenia prevent us from examining the role of
prolonged exposure or changes in exposure, which may be
important predictors of our outcomes of interest. Other risk
factors for our outcomes may also have been time varying,
making choice of covariates for confounder adjustment
complex. Since the data available for both exposure and
A B
Figure 5. Associations between HGS (left) BMI (middle) and WHR (right) variants, and possible pleiotropic
variables. BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; HGS, hand-grip
strength; WHR, waist-hip-ratio; SBP, systolic blood pressure.
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covariates were all measured at a single time point, our
analysis relies on making assumptions about which covariates
are likely to have inﬂuenced the exposure at that point, versus
which may have been a consequence of the measured
exposure (so should not be adjusted for). Provided the
assumptions of MR were satisﬁed, our analysis using genetic
risk scores is robust to both of these limitations of the
observational analysis.
Conclusions
Our analyses do not support the concept of a “healthy obese”
phenotype in relationship to muscle mass or grip strength.
WHR, BMI, and fat mass deﬁned obesity appear similar in their
association with future cardiovascular risk and mortality, in
that in general, increased adiposity increases risk. Lower-grip
strength was associated with increased risks of cardiovascu-
lar and all-cause mortality in a multivariable regression and
MR analysis, suggesting reverse causality may not be the sole
explanation. Grip strength appears to be a good prognostic
indicator for mortality risk in adults with and without obesity,
though it is not yet clear whether interventions to improve
muscle strength would directly decrease risk.
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Table S1. Genetic Quality Control (QC) details. 
 
Level QC operation Notes 
Individual Sex mismatch Drop patients with a mismatch between genetic sex and self-
reported sex at baseline 
Individual Recommended UK BeLIVE 
exclusions 
  
Recommended by UK Biobank for the 50,005 patients 
genotyped using UK BeLIVE. 
Individual Recommend exclusion Recommended genomic exclusion for poor 
heterozygosity/missingness 
Individual Genetic relatedness Kinship coefficient 0.044 – remove all related individuals 
Individual Population origin Drop non-CEU participants 
Individual Heterozygosity Filter out samples with heterozygosity (as taken from the 
"heterozygosity" column of the sample file, which must be 
present) outside the interval [0.18,0.2] 
Individual Sample-missing-rate Filter out samples with missing data rate (as taken from the 
"missing" column of the sample file) greater than 5%  
SNP‡ Information score Filter out SNPs with Fisher information < 0.3 
SNP SNP missing call rate Filter out SNPs with missing call rate greater than or equal 5%  
SNP Hardy-Weinberg Equilibrium HWE threshold -log10(p-value) <= 1x10-6 
 
SNP Minor Allele Frequency MAF outside 0.01-1 range 
 
SNP  SNP missing rate Filter out SNPs with missing data rate greater than or equal to 
5% 
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Table S2. Waist hip ratio SNPs identified from previous study, and internal/external weights 
used for MR analyses. 
Waist Hip Ratio  
Rsid  Effect 
Allele  
MAF 
internal  
Internal 
Weight 
MAF 
external  
External 
Weight  
Included in Genetic Risk Score  
  
        
rs10195252 T 0.594 0.122 0.558 0.027 
rs10245353 A 0.176 0.206 0.183 0.035 
rs1045241 C 0.742 0.058 0.692 0.019 
rs10804591 A 0.790 0.138 0.850 0.024 
rs10842707 T 0.208 0.179 0.167 0.032 
rs10919388 C 0.761 0.196 0.717 0.024 
rs10991437 A 0.117 0.248 0.100 0.031 
rs11231693 A 0.049 0.226 0.042 0.041 
rs12454712 T 0.624 0.053 0.633 0.016 
rs12608504 A 0.365 0.127 0.342 0.022 
rs12679556 G 0.235 0.108 0.208 0.027 
rs1294410 C 0.622 0.171 0.625 0.031 
rs1358980 T 0.460 0.197 0.450 0.039 
rs1385167 G 0.123 0.078 0.142 0.029 
rs1440372 C 0.751 0.068 0.742 0.024 
rs1443512 A 0.217 0.200 0.200 0.028 
rs1534696 C 0.461 0.165 0.350 0.011 
rs1569135 A 0.552 0.234 0.533 0.021 
rs1776897 G 0.089 0.232 0.075 0.03 
rs17819328 G 0.418 0.184 0.450 0.021 
rs1936805 T 0.519 0.226 0.550 0.042 
rs224333 G 0.642 0.011 0.667 0.02 
rs2276824 C 0.439 0.099 0.483 0.024 
rs2294239 A 0.572 0.146 0.550 0.025 
rs2371767 G 0.738 0.248 0.792 0.036 
rs2645294 T 0.571 0.209 0.535 0.031 
rs2820443 T 0.704 0.214 0.700 0.035 
rs2925979 T 0.301 0.149 0.283 0.018 
rs303084 A 0.794 0.150 0.783 0.023 
rs3805389 A 0.243 0.049 0.242 0.012 
rs4081724 G 0.870 0.126 0.850 0.035 
rs4646404 G 0.670 0.129 0.625 0.027 
rs4765219 C 0.667 0.185 0.625 0.028 
rs6556301 T 0.357 0.146 0.375 0.022 
rs714515 G 0.436 0.193 0.458 0.027 
rs7705502 A 0.298 0.037 0.292 0.027 
rs7830933 A 0.776 0.091 0.742 0.022 
rs7917772 A 0.632 0.046 0.683 0.014 
rs8030605 A 0.124 0.004 0.158 0.03 
rs8066985 A 0.485 0.126 0.517 0.018 
rs905938 T 0.733 0.101 0.675 0.025 
rs9687846 A 0.201 0.167 0.192 0.024 
rs979012 T 0.365 0.085 0.358 0.027 
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rs9991328 T 0.458 0.113 0.483 0.018 
  
    
  
Excluded SNPs that did not 
pass the overall QC in our 
data processing step 
          
rs17451107 
    
  
rs6090583 
    
  
rs7759742 
    
  
rs7801581 
    
  
rs8042543 
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Table S3. BMI SNPs and internal/external weights used for MR analyses. 
 
BMI  
Rsid  Effect 
Allele  
MAF 
internal  
Internal 
Weight 
MAF 
external  
External 
Weight  
Included in Genetic Risk Score  
  
        
rs1000940 G 0.30 0.060 0.225 0.019 
rs10132280 C 0.72 0.085 0.667 0.023 
rs1016287 T 0.30 0.102 0.325 0.023 
rs10182181 G 0.49 0.159 0.500 0.031 
rs10938397 G 0.43 0.134 0.433 0.040 
rs10968576 G 0.32 0.119 0.292 0.025 
rs11030104 A 0.80 0.204 0.800 0.041 
rs11057405 G 0.89 0.132 0.908 0.031 
rs11126666 A 0.25 0.004 0.308 0.021 
rs11165643 T 0.60 0.073 0.575 0.022 
rs11191560 C 0.08 0.147 0.058 0.031 
rs11583200 C 0.40 0.091 0.375 0.018 
rs1167827 G 0.57 0.111 0.542 0.020 
rs11688816 G 0.56 0.060 0.458 0.017 
rs11727676 T 0.90 0.020 0.925 0.036 
rs11847697 T 0.04 0.057 0.042 0.049 
rs12286929 G 0.52 0.035 0.433 0.022 
rs12401738 A 0.37 0.065 0.425 0.021 
rs12429545 A 0.12 0.124 0.100 0.033 
rs12446632 G 0.86 0.107 0.867 0.040 
rs12566985 G 0.43 0.052 0.425 0.024 
rs12885454 C 0.65 0.077 0.633 0.021 
rs12940622 G 0.56 0.093 0.542 0.018 
rs13021737 G 0.84 0.295 0.875 0.060 
rs13078960 G 0.20 0.097 0.183 0.030 
rs13107325 T 0.07 0.209 0.117 0.048 
rs13191362 A 0.88 0.130 0.800 0.028 
rs13201877 G 0.10 0.038 0.083 0.023 
rs1441264 A 0.61 0.079 0.550 0.018 
rs1460676 C 0.15 0.079 0.217 0.020 
rs1516725 C 0.87 0.158 0.908 0.045 
rs1528435 T 0.63 0.072 0.583 0.018 
rs1558902 A 0.40 0.384 0.450 0.082 
rs16851483 T 0.07 0.141 0.092 0.048 
rs16907751 C 0.92 0.116 0.958 0.035 
rs16951275 T 0.77 0.163 0.775 0.031 
rs17024393 C 0.02 0.384 0.042 0.066 
rs17094222 C 0.18 0.075 0.208 0.025 
rs17203016 G 0.18 0.080 0.200 0.021 
rs17405819 T 0.70 0.073 0.633 0.022 
rs17724992 A 0.76 0.112 0.692 0.019 
rs1808579 C 0.51 0.104 0.525 0.017 
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rs1928295 T 0.57 0.051 0.575 0.019 
rs2033732 C 0.74 0.016 0.758 0.019 
rs205262 G 0.26 0.143 0.267 0.022 
rs2080454 C 0.39 0.068 0.392 0.017 
rs2112347 T 0.64 0.121 0.625 0.026 
rs2121279 T 0.12 0.017 0.117 0.025 
rs2176040 A 0.35 0.043 0.392 0.014 
rs2176598 T 0.25 0.117 0.200 0.020 
rs2207139 G 0.17 0.203 0.100 0.045 
rs2287019 C 0.84 0.180 0.850 0.036 
rs2365389 C 0.59 0.135 0.658 0.020 
rs2650492 A 0.27 0.001 0.308 0.021 
rs2820292 C 0.57 0.101 0.508 0.020 
rs2836754 C 0.64 0.062 0.650 0.016 
rs29941 G 0.67 0.090 0.667 0.018 
rs3101336 C 0.60 0.129 0.649 0.033 
rs3736485 A 0.46 0.057 0.425 0.018 
rs3810291 A 0.68 0.135 0.625 0.028 
rs3817334 T 0.41 0.143 0.450 0.026 
rs3849570 A 0.32 0.032 0.367 0.019 
rs3888190 A 0.41 0.111 0.358 0.031 
rs4256980 G 0.66 0.103 0.725 0.021 
rs4740619 T 0.55 0.067 0.533 0.018 
rs4787491 G 0.55 0.095 0.614 0.016 
rs492400 C 0.43 0.016 0.325 0.016 
rs543874 G 0.21 0.237 0.267 0.048 
rs6091540 C 0.73 0.094 0.725 0.019 
rs6465468 T 0.27 0.005 0.325 0.017 
rs6477694 C 0.35 0.025 0.358 0.017 
rs6567160 C 0.23 0.235 0.283 0.056 
rs657452 A 0.40 0.002 0.417 0.023 
rs6804842 G 0.56 0.058 0.575 0.019 
rs7138803 A 0.37 0.162 0.442 0.032 
rs7141420 T 0.52 0.091 0.617 0.024 
rs7164727 T 0.67 0.108 0.775 0.018 
rs7239883 G 0.38 0.063 0.317 0.016 
rs7243357 T 0.84 0.066 0.867 0.022 
rs758747 T 0.25 0.079 0.267 0.023 
rs7599312 G 0.76 0.093 0.708 0.022 
rs7715256 G 0.43 0.072 0.450 0.016 
rs7899106 G 0.05 0.090 0.050 0.040 
rs7903146 C 0.71 0.130 0.750 0.023 
rs9374842 T 0.78 0.057 0.742 0.019 
rs9400239 C 0.71 0.082 0.700 0.019 
rs9540493 A 0.47 0.068 0.450 0.017 
rs9641123 C 0.40 0.054 0.392 0.019 
rs977747 T 0.42 0.087 0.467 0.017 
rs9914578 G 0.20 0.030 0.167 0.020 
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Excluded SNPs that did not 
pass the overall QC in our 
data processing step 
          
rs10733682 
    
  
rs12016871 
    
  
rs17001654 
    
  
rs2033529 
    
  
rs2075650 
    
  
rs9925964 
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 Table S4. Hand grip strength SNPs and internal/external weights used for MR analyses. 
 
Hand Grip Strength  
Rsid  Effect 
Allele  
MAF 
internal  
Internal 
Weight 
MAF 
external  
External 
Weight  
Included in Genetic Risk Score  
  
        
rs10186876 A 0.353 0.102 0.360 0.113 
rs10861798 A 0.429 0.225 0.430 0.159 
rs2110927 C 0.261 0.130 0.270 0.098 
rs2273555 A 0.607 0.169 0.610 0.096 
rs2288278 A 0.658 0.150 0.660 0.147 
rs374532236 T 0.357 0.185 0.380 0.121 
rs4926611 C 0.643 0.117 0.640 0.115 
rs6565586 A 0.243 0.190 0.250 0.096 
rs6687430 G 0.459 0.166 0.460 0.125 
rs72762373 A 0.019 0.681 0.030 0.359 
rs72979233 A 0.756 0.185 0.760 0.112 
rs958685 A 0.516 0.143 0.520 0.164 
  
    
  
Excluded SNPs that did not 
pass the overall QC in our 
data processing step 
          
rs11614333 
    
  
rs34845616 
    
  
rs78325334 
    
  
rs80103986 
    
  
 
 
D
ow
nloaded from
 http://ahajournals.org by on June 27, 2019
Table S5. Adjusted* hazard (with 95% confidence interval) ratios of combined fatal/non CHD 
events and mortality by quintiles of BMI and HGS for those without history of CVD. 
 
B
M
I Q
u
in
ti
le
 (
kg
/m
2)
 
 Fatal/non-fatal CHD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
12-23 
1 (ref) 0.84 (0.59 , 1.19) 1.01 (0.71 , 1.43) 1.02 (0.71 , 1.47) 1.64 (1.18 , 2.29) 
0.101 
23-26 
1.15 (0.84 , 1.57) 1.28 (0.94 , 1.73) 1.34 (0.97 , 1.85) 1.78 (1.28 , 2.48) 1.57 (1.12 , 2.21) 
26-28 
1.47 (1.09 , 1.97) 1.51 (1.12 , 2.02) 1.7 (1.25 , 2.31) 1.69 (1.21 , 2.36) 1.89 (1.36 , 2.64) 
28-31 
1.47 (1.1 , 1.98) 1.6 (1.2 , 2.15) 1.81 (1.33 , 2.46) 1.88 (1.35 , 2.61) 2.21 (1.59 , 3.05) 
31-60 
2.32 (1.74 , 3.09) 1.76 (1.31 , 2.37) 2.41 (1.78 , 3.26) 2.36 (1.72 , 3.25) 2.59 (1.89 , 3.54) 
  CHD Mortality 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
12-23 
1 (ref) 0.94 (0.5 , 1.8) 1.18 (0.6 , 2.32) 1.49 (0.72 , 3.08) 3.44 (1.82 , 6.51) 
0.342 
23-26 
0.97 (0.52 , 1.8) 1.13 (0.63 , 2.04) 1.4 (0.74 , 2.64) 2.72 (1.44 , 5.12) 3.09 (1.61 , 5.93) 
26-28 
1.17 (0.66 , 2.08) 1.38 (0.78 , 2.43) 1.4 (0.75 , 2.61) 1.44 (0.7 , 2.97) 3.64 (1.93 , 6.87) 
28-31 
1.4 (0.8 , 2.46) 1.33 (0.75 , 2.34) 1.73 (0.95 , 3.15) 2.6 (1.39 , 4.86) 3.12 (1.64 , 5.94) 
31-60 
1.75 (1 , 3.08) 1.77 (1.01 , 3.11) 2.49 (1.4 , 4.43) 2.7 (1.43 , 5.08) 2.73 (1.44 , 5.17) 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation. BMI – body mass index HGS – hand grip strength 
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Table S6. Adjusted* hazard (with 95% confidence interval) ratios of combined fatal/non CHD 
events and mortality by quintiles of BMI and HGS for those with history of CVD. 
 
B
M
I Q
u
in
ti
le
 (
kg
/m
2)
 
 Fatal/non-fatal CHD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interactio
n 
12-23 
1 (ref) 1.24 (0.82 , 1.87) 1.16 (0.76 , 1.77) 0.97 (0.62 , 1.52) 1.46 (0.98 , 2.19) 
0.455 
23-26 
1.45 (0.98 , 2.15) 1.77 (1.22 , 2.58) 1.88 (1.28 , 2.76) 1.41 (0.93 , 2.13) 1.73 (1.16 , 2.57) 
26-28 
1.78 (1.23 , 2.59) 1.8 (1.25 , 2.6) 1.8 (1.24 , 2.62) 1.98 (1.34 , 2.93) 2 (1.36 , 2.94) 
28-31 
1.84 (1.28 , 2.65) 1.92 (1.34 , 2.76) 1.68 (1.16 , 2.45) 1.76 (1.2 , 2.6) 2.18 (1.49 , 3.18) 
31-60 
2.47 (1.73 , 3.54) 2.24 (1.57 , 3.21) 2.29 (1.59 , 3.29) 2.3 (1.58 , 3.33) 2.81 (1.95 , 4.05) 
  CHD Mortality 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interactio
n 
12-23 
1 (ref) 1.83 (0.6 , 5.56) 2.32 (0.77 , 7) 4.32 (1.45 , 12.84) 4.23 (1.44 , 12.49) 
0.745 
23-26 
2.07 (0.7 , 6.09) 2.28 (0.81 , 6.45) 2.84 (0.99 , 8.19) 2.66 (0.88 , 8.07) 3.98 (1.35 , 11.73) 
26-28 
2.03 (0.71 , 5.78) 2.09 (0.75 , 5.83) 3.05 (1.09 , 8.55) 4.05 (1.41 , 11.62) 3.06 (1.04 , 9) 
28-31 
1.62 (0.57 , 4.6) 2.45 (0.89 , 6.74) 2.68 (0.96 , 7.45) 2.8 (0.97 , 8.06) 2.81 (0.97 , 8.15) 
31-60 
2.49 (0.9 , 6.87) 2.99 (1.1 , 8.15) 3.17 (1.15 , 8.7) 3.46 (1.24 , 9.67) 4.21 (1.51 , 11.69) 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation. BMI – body mass index HGS – hand grip strength 
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Table S7. Distribution of Obesity and Sarcopenia at baseline by sex. 
 
  Overall Male Female 
BMI and grip Strength N % N % N % 
Non-Obese/Non-Sarcopenic 296,567 65.5% 140,302 68.3% 156,265 63.2% 
Obese 89,906 19.8% 45,979 22.4% 43,927 17.8% 
Sarcopenic 48,250 10.7% 13,820 6.7% 34,430 13.9% 
Sarcopenic Obesity 18,208 4.0% 5,467 2.7% 12,741 5.2% 
BMI  and SMMI N % N % N % 
Non-Obese/Non-Sarcopenic 170,532 38.1% 75,449 37.2% 95,083 38.9% 
Obese 96,354 21.5% 45,824 22.6% 50,530 20.6% 
Sarcopenic 170,428 38.1% 76,764 37.8% 93,664 38.3% 
Sarcopenic Obesity 10,247 2.3% 4,790 2.4% 5,457 2.2% 
WHR and grip Strength N % N % N % 
Non-Obese/Non-Sarcopenic 206,533 45.5% 115,795 56.2% 90,738 36.6% 
Obese 182,592 40.2% 71,634 34.8% 110,958 44.8% 
Sarcopenic 23,714 5.2% 8,402 4.1% 15,312 6.2% 
Sarcopenic Obesity 40,842 9.0% 10,187 4.9% 30,655 12.4% 
WHR and SMMI N % N % N % 
Non-Obese/Non-Sarcopenic 125,213 28.0% 68,397 33.7% 56,816 23.2% 
Obese 144,608 32.3% 54,738 27.0% 89,870 36.7% 
Sarcopenic 102,360 22.9% 54,227 26.7% 48,133 19.7% 
Sarcopenic Obesity 75,308 16.8% 25,420 12.5% 49,888 20.4% 
WHR – waist hip ratio, BMI – body mass index HGS – hand grip strength SMMI – skeletal muscle mass index
D
ow
nloaded from
 http://ahajournals.org by on June 27, 2019
 Table S8. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD 
mortality, and combined fatal/non CVD events by quintiles of BMI and SMMI in those 
without with a history of CVD. 
 
  All-cause mortality 
  SMMI Quintile  
B
M
I Q
u
in
ti
le
 (
kg
/m
2)
 
 9.2-31.2 8.3-9.2 7.0-8.3 6.3-7.0 4.2-6.3 
P value for 
interaction 
12-23 
1 (ref) 0.8 (0.58 , 1.1) 1 (0.73 , 1.36) 1.02 (0.73 , 1.43) 0.87 (0.63 , 1.21) 
0.061 
23-26 
0.80 (0.57 , 1.13) 0.74 (0.55 , 1.01) 0.90 (0.66 , 1.23) 0.80 (0.57 , 1.12) 0.86 (0.62 , 1.19) 
26-28 
0.72 (0.52 , 0.99) 0.76 (0.56 , 1.03) 0.96 (0.69 , 1.32) 0.82 (0.58 , 1.15) 0.81 (0.58 , 1.14) 
28-31 
0.84 (0.62 , 1.13) 0.86 (0.63 , 1.17) 0.92 (0.66 , 1.28) 0.79 (0.56 , 1.11) 0.95 (0.67 , 1.34) 
31-60 
0.97 (0.71 , 1.30) 0.99 (0.72 , 1.36) 0.92 (0.66 , 1.27) 0.88 (0.62 , 1.24) 0.97 (0.65 , 1.44) 
 Fatal/non-fatal CVD 
 SMMI Quintile 
 9.2-31.2 8.3-9.2 7.0-8.3 6.3-7.0 4.2-6.3 
P value for 
interaction 
12-23 
1 (ref) 1.28 (0.92 , 1.78) 1.36 (0.98 , 1.88) 1.31 (0.93 , 1.84) 1.20 (0.86 , 1.68) 
0.004 
23-26 
1.43 (1.02 , 2.01) 1.35 (0.98 , 1.87) 1.19 (0.86 , 1.65) 1.28 (0.91 , 1.81) 1.42 (1.02 , 1.99) 
26-28 
1.38 (1.00 , 1.91) 1.47 (1.07 , 2.02) 1.68 (1.21 , 2.34) 1.32 (0.94 , 1.86) 1.37 (0.97 , 1.92) 
28-31 
1.60 (1.17 , 2.20) 1.51 (1.09 , 2.08) 1.65 (1.18 , 2.31) 1.47 (1.04 , 2.06) 1.54 (1.09 , 2.19) 
31-60 
2.00 (1.46 , 2.74) 1.92 (1.38 , 2.66) 1.83 (1.32 , 2.56) 1.61 (1.14 , 2.27) 1.93 (1.32 , 2.82) 
 Fatal CVD 
 SMMI Quintile 
 9.2-31.2 8.3-9.2 7.0-8.3 6.3-7.0 4.2-6.3 
P value for 
interaction 
12-23 
1 (ref) 1.49 (0.64 , 3.45) 1.85 (0.81 , 4.23) 1.77 (0.73 , 4.34) 1.37 (0.57 , 3.27) 
0.297 
23-26 
1.44 (0.6 , 3.45) 1.43 (0.63 , 3.25) 1.56 (0.68 , 3.6) 1.43 (0.58 , 3.53) 1.86 (0.78 , 4.47) 
26-28 
1.27 (0.55 , 2.93) 1.4 (0.62 , 3.19) 1.61 (0.69 , 3.77) 1.32 (0.53 , 3.25) 1.32 (0.54 , 3.27) 
28-31 
1.78 (0.79 , 4.02) 1.62 (0.71 , 3.68) 2.1 (0.89 , 4.96) 1.37 (0.56 , 3.37) 2.22 (0.9 , 5.45) 
31-60 
2.34 (1.04 , 5.27) 1.91 (0.82 , 4.44) 2.32 (0.98 , 5.5) 1.4 (0.56 , 3.5) 1.68 (0.6 , 4.71) 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation BMI- body mass index. SMMI – skeletal muscle mass index 
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Table S9. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD 
mortality, and combined fatal/non CVD events by quintiles of BMI and SMMI in those with 
with a history of CVD. 
 
  All-cause mortality 
  SMMI Quintile  
B
M
I Q
u
in
ti
le
 (
kg
/m
2)
 
 9.2-31.2 8.3-9.2 7.0-8.3 6.3-7.0 4.2-6.3 
P value for 
interaction 
12-23 
1 (ref) 0.66 (0.36 , 1.24) 0.93 (0.51 , 1.68) 1.24 (0.65 , 2.36) 1.06 (0.57 , 1.97) 
0.012 
23-26 
0.83 (0.44 , 1.56) 0.69 (0.38 , 1.25) 0.85 (0.47 , 1.54) 0.72 (0.37 , 1.4) 0.65 (0.34 , 1.23) 
26-28 
0.69 (0.38 , 1.25) 0.65 (0.36 , 1.17) 0.91 (0.5 , 1.65) 0.72 (0.37 , 1.38) 0.65 (0.34 , 1.25) 
28-31 
0.65 (0.36 , 1.16) 0.77 (0.43 , 1.37) 0.63 (0.34 , 1.17) 0.7 (0.37 , 1.33) 0.54 (0.27 , 1.07) 
31-60 
0.79 (0.45 , 1.41) 0.9 (0.5 , 1.61) 0.9 (0.49 , 1.67) 0.79 (0.42 , 1.5) 0.76 (0.36 , 1.57) 
 Fatal/non-fatal CVD 
 SMMI Quintile 
 9.2-31.2 8.3-9.2 7.0-8.3 6.3-7.0 4.2-6.3 
P value for 
interaction 
12-23 
1 (ref) 0.79 (0.49 , 1.27) 0.93 (0.59 , 1.48) 0.89 (0.54 , 1.46) 0.93 (0.58 , 1.48) 
0.281 
23-26 
1.08 (0.67 , 1.75) 0.9 (0.57 , 1.41) 1.12 (0.71 , 1.76) 0.97 (0.6 , 1.58) 0.96 (0.59 , 1.54) 
26-28 
1.06 (0.67 , 1.68) 1.02 (0.65 , 1.59) 1.17 (0.74 , 1.84) 0.84 (0.52 , 1.36) 1.02 (0.63 , 1.64) 
28-31 
1.02 (0.66 , 1.6) 1.04 (0.67 , 1.63) 1.17 (0.74 , 1.87) 1.02 (0.63 , 1.64) 0.94 (0.58 , 1.54) 
31-60 
1.37 (0.88 , 2.13) 1.13 (0.72 , 1.78) 1.23 (0.77 , 1.96) 1.17 (0.73 , 1.88) 1.09 (0.64 , 1.84) 
 Fatal CVD 
 SMMI Quintile 
 9.2-31.2 8.3-9.2 7.0-8.3 6.3-7.0 4.2-6.3 
P value for 
interaction 
12-23 
1 (ref) 0.34 (0.16 , 0.74) 0.53 (0.26 , 1.07) 0.42 (0.17 , 1.02) 0.53 (0.24 , 1.14) 
0.05 
23-26 
0.43 (0.2 , 0.96) 0.40 (0.20 , 0.80) 0.5 (0.25 , 1.02) 0.36 (0.15 , 0.86) 0.27 (0.11 , 0.63) 
26-28 
0.42 (0.2 , 0.85) 0.40 (0.20 , 0.8)0 0.55 (0.27 , 1.13) 0.3 (0.12 , 0.72) 0.32 (0.14 , 0.74) 
28-31 
0.4 (0.2 , 0.79) 0.45 (0.23 , 0.89) 0.41 (0.19 , 0.86) 0.39 (0.17 , 0.89) 0.2 (0.08 , 0.53) 
31-60 
0.58 (0.29 , 1.12) 0.59 (0.30 , 1.18) 0.4 (0.19 , 0.86) 0.4 (0.18 , 0.9) 0.3 (0.1 , 0.88) 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation BMI- body mass index. SMMI – skeletal muscle mass index 
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Table S10. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD 
mortality, and combined fatal/non CVD events by quintiles of WHR and HGS in participants 
without history of CVD. 
 
  All-cause mortality 
  HGS Quintile (kg) 
W
H
R
 Q
u
in
ti
le
  
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
0.44-0.79 1 (ref) 1.01 (0.56 , 1.83) 1.02 (0.59 , 1.76) 1.18 (0.69 , 2.02) 1.29 (0.76 , 2.21) 
0.138 
0.79-0.85 0.66 (0.37 , 1.17) 0.71 (0.40 , 1.24) 1.10 (0.64 , 1.90) 1.18 (0.69 , 2.02) 1.48 (0.87 , 2.53) 
0.85-0.90 0.77 (0.45 , 1.32) 0.90 (0.53 , 1.54) 1.11 (0.65 , 1.91) 1.22 (0.71 , 2.09) 1.47 (0.86 , 2.51) 
0.90-0.95 0.78 (0.46 , 1.33) 1.03 (0.60 , 1.75) 1.17 (0.68 , 1.99) 1.33 (0.77 , 2.28) 1.63 (0.95 , 2.80) 
0.95-1.30 1.13 (0.67 , 1.92) 1.17 (0.69 , 2.00) 1.47 (0.86 , 2.49) 1.70 (0.99 , 2.90) 1.77 (1.03 , 3.05) 
 Fatal/non-fatal CVD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
0.44-0.79 1 (ref) 1.33 (0.79 , 2.23) 1.24 (0.76 , 2.02) 1.17 (0.72 , 1.90) 1.18 (0.72 , 1.92) 
0.500 
0.79-0.85 1.42 (0.86 , 2.34) 1.32 (0.80 , 2.16) 1.45 (0.89 , 2.36) 1.41 (0.87 , 2.29) 1.37 (0.84 , 2.23) 
0.85-0.90 1.34 (0.83 , 2.18) 1.29 (0.79 , 2.09) 1.46 (0.90 , 2.38) 1.49 (0.92 , 2.43) 1.52 (0.93 , 2.47) 
0.90-0.95 1.55 (0.96 , 2.50) 1.60 (0.99 , 2.59) 1.56 (0.96 , 2.54) 1.47 (0.90 , 2.40) 1.63 (1.00 , 2.66) 
0.95-1.30 1.86 (1.15 , 3.00) 1.69 (1.04 , 2.72) 1.89 (1.16 , 3.06) 1.87 (1.15 , 3.05) 1.88 (1.15 , 3.07) 
 Fatal CVD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
0.44-0.79 1 (ref) 1.41 (0.40 , 5.02) 0.76 (0.22 , 2.57) 1.06 (0.33 , 3.44) 1.13 (0.35 , 3.65) 
0.418 
0.79-0.85 0.81 (0.24 , 2.75) 0.68 (0.20 , 2.32) 1.21 (0.37 , 3.95) 1.29 (0.40 , 4.17) 1.83 (0.57 , 5.84) 
0.85-0.90 0.83 (0.26 , 2.64) 0.83 (0.26 , 2.66) 1.12 (0.35 , 3.60) 1.22 (0.38 , 3.93) 1.69 (0.53 , 5.42) 
0.90-0.95 0.84 (0.26 , 2.64) 1.14 (0.36 , 3.58) 1.22 (0.38 , 3.87) 1.74 (0.54 , 5.57) 1.92 (0.60 , 6.17) 
0.95-1.30 1.30 (0.41 , 4.07) 1.31 (0.42 , 4.10) 1.78 (0.57 , 5.58) 2.16 (0.68 , 6.85) 2.32 (0.73 , 7.39) 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation. WHR- waist hip ratio. HGS – hand grip strength 
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Table S11. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD 
mortality, and combined fatal/non CVD events by quintiles of WHR and HGS in participants 
with history of CVD. 
 
  All-cause mortality 
  HGS Quintile (kg) 
W
H
R
 Q
u
in
ti
le
  
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
0.44-
0.79 1 (ref) 1.73 (0.38 , 7.91) 1.26 (0.3 , 5.34) 1.63 (0.4 , 6.73) 1.6 (0.39 , 6.55) 
0.911 
0.79-
0.85 0.98 (0.23 , 4.28) 1.35 (0.32 , 5.64) 1.33 (0.32 , 5.49) 1.77 (0.43 , 7.22) 2.14 (0.53 , 8.68) 
0.85-
0.90 1.09 (0.27 , 4.45) 1.23 (0.3 , 5.01) 1.6 (0.39 , 6.51) 1.86 (0.45 , 7.58) 2.05 (0.51 , 8.34) 
0.90-
0.95 1.1 (0.27 , 4.47) 1.26 (0.31 , 5.1) 1.7 (0.42 , 6.88) 1.89 (0.47 , 7.68) 2.31 (0.57 , 9.35) 
0.95-
1.30 1.49 (0.37 , 5.99) 1.59 (0.39 , 6.38) 1.81 (0.45 , 7.27) 2.28 (0.56 , 9.2) 2.75 (0.68 , 11.1) 
 Fatal/non-fatal CVD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
0.44-
0.79 1 (ref) 1.15 (0.51 , 2.62) 0.85 (0.39 , 1.83) 0.94 (0.44 , 2) 1.04 (0.49 , 2.21) 
0.706 
0.79-
0.85 1.33 (0.61 , 2.9) 0.98 (0.45 , 2.13) 1.18 (0.55 , 2.52) 1.09 (0.51 , 2.32) 1.11 (0.52 , 2.35) 
0.85-
0.90 1.08 (0.51 , 2.3) 1.11 (0.52 , 2.36) 1.19 (0.56 , 2.54) 1.15 (0.54 , 2.44) 1.21 (0.57 , 2.57) 
0.90-
0.95 1.11 (0.53 , 2.34) 1.21 (0.57 , 2.55) 1.22 (0.58 , 2.58) 1.18 (0.55 , 2.51) 1.32 (0.62 , 2.81) 
0.95-
1.30 1.34 (0.63 , 2.81) 1.27 (0.6 , 2.68) 1.33 (0.63 , 2.81) 1.33 (0.63 , 2.81) 1.46 (0.69 , 3.09) 
 Fatal CVD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
0.44-
0.79 1 (ref) 2.03 (0.24 , 17.5) 0.81 (0.1 , 6.79) 1.07 (0.14 , 8.2) 1.35 (0.18 ,10.03) 
0.418 
0.79-
0.85 0.35 (0.04 , 3.41) 1.15 (0.15 , 8.8) 1.42 (0.19 ,10.68) 1.76 (0.24 ,12.99) 1.83 (0.25 ,13.38) 
0.85-
0.90 0.81 (0.11 , 6.04) 1.09 (0.15 , 7.97) 1.39 (0.19 ,10.21) 1.66 (0.22 ,12.22) 1.53 (0.21 ,11.18) 
0.90-
0.95 0.79 (0.11 , 5.75) 1.16 (0.16 , 8.37) 1.36 (0.19 , 9.83) 1.49 (0.2 , 10.91) 2.04 (0.28 ,14.81) 
0.95-
1.30 1.24 (0.17 , 8.89) 1.43 (0.2 , 10.26) 1.65 (0.23 ,11.87) 2.14 (0.3 , 15.4) 2.61 (0.36 ,18.76) 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation. WHR- waist hip ratio. HGS – hand grip strength 
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Table S12. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD 
mortality, and combined fatal/non CVD events by quintiles of Fat mass (%) and HGS in 
participants without history of CVD. 
 
  All-cause mortality 
  HGS Quintile (kg) 
Fa
t 
m
as
s 
q
u
in
ti
le
 (
%
) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
5-23.8 
1 (ref) 1.39 (1.23 , 1.58) 1.82 (1.57 , 2.10) 2.21 (1.84 , 2.65) 3.12 (2.57 , 3.78) 
<0.001 
23.9-
28.6 1.23 (1.08 , 1.41) 1.34 (1.17 , 1.52) 1.55 (1.34 , 1.80) 1.87 (1.58 , 2.23) 2.64 (2.21 , 3.16) 
28.7-
33.5 1.42 (1.23 , 1.65) 1.49 (1.29 , 1.71) 1.77 (1.53 , 2.06) 2.00 (1.70 , 2.35) 2.10 (1.78 , 2.48) 
33.6-
39.2 1.61 (1.29 , 2.01) 1.65 (1.37 , 1.99) 1.82 (1.54 , 2.15) 2.02 (1.73 , 2.36) 2.22 (1.90 , 2.59) 
39.3-
69.8 2.89 (1.88 , 4.45) 1.58 (1.17 , 2.14) 2.04 (1.70 , 2.44) 2.05 (1.75 , 2.41) 2.52 (2.16 , 2.93) 
 Fatal/non-fatal CVD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
5-23.8 
1 (ref) 1.02 (0.93 , 1.13) 1.05 (0.93 , 1.19) 1.22 (1.03 , 1.43) 1.41 (1.17 , 1.70) 
0.002 
23.9-
28.6 1.23 (1.12 , 1.36) 1.09 (0.99 , 1.21) 1.22 (1.09 , 1.37) 1.11 (0.95 , 1.29) 1.21 (1.02 , 1.43) 
28.7-
33.5 1.26 (1.13 , 1.41) 1.24 (1.12 , 1.39) 1.25 (1.11 , 1.41) 1.31 (1.15 , 1.49) 1.22 (1.06 , 1.41) 
33.6-
39.2 1.64 (1.39 , 1.94) 1.46 (1.26 , 1.68) 1.51 (1.33 , 1.72) 1.45 (1.28 , 1.65) 1.30 (1.14 , 1.48) 
39.3-
69.8 1.44 (0.93 , 2.25) 1.64 (1.32 , 2.03) 1.78 (1.55 , 2.04) 1.60 (1.41 , 1.81) 1.77 (1.57 , 2.00) 
 Fatal CVD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
5-23.8 
1 (ref) 1.32 (1.02 , 1.72) 1.64 (1.21 , 2.22) 2.84 (2 , 4.04) 3.67 (2.48 , 5.42) 
0.050 
23.9-
28.6 1.41 (1.08 , 1.83) 1.38 (1.06 , 1.81) 1.68 (1.25 , 2.26) 2.20 (1.54 , 3.13) 2.86 (1.93 , 4.22) 
28.7-
33.5 1.59 (1.18 , 2.13) 1.64 (1.24 , 2.17) 1.99 (1.47 , 2.7) 2.24 (1.58 , 3.17) 2.59 (1.81 , 3.71) 
33.6-
39.2 2.02 (1.34 , 3.05) 2.12 (1.49 , 3.02) 2.38 (1.69 , 3.37) 2.42 (1.71 , 3.44) 2.82 (2.02 , 3.95) 
39.3-
69.8 2.81 (1.14 , 6.9) 2.43 (1.32 , 4.46) 3.19 (2.17 , 4.7) 2.92 (2.05 , 4.17) 3.74 (2.70 , 5.17) 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation HGS – hand grip strength 
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Table S13. Adjusted* hazard (with 95% confidence interval) ratios of all-cause and CVD 
mortality, and combined fatal/non CVD events by quintiles of Fat mass (%) and HGS in 
participants with history of CVD. 
 
  All-cause mortality 
  HGS Quintile (kg) 
Fa
t 
m
as
s 
q
u
in
ti
le
 (
%
) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
5-23.8 
1 (ref) 1 (0.79 , 1.27) 1.54 (1.2 , 1.96) 2.08 (1.56 , 2.79) 2.54 (1.86 , 3.46) 
0.002 
23.9-
28.6 0.9 (0.71 , 1.14) 1.13 (0.9 , 1.4) 1.13 (0.88 , 1.45) 1.41 (1.06 , 1.89) 1.75 (1.31 , 2.36) 
28.7-
33.5 1.12 (0.88 , 1.42) 1.09 (0.87 , 1.36) 1.2 (0.94 , 1.52) 1.74 (1.35 , 2.24) 1.93 (1.49 , 2.5) 
33.6-
39.2 1.36 (0.99 , 1.85) 1.37 (1.05 , 1.77) 1.43 (1.11 , 1.86) 1.6 (1.22 , 2.11) 1.57 (1.21 , 2.05) 
39.3-
69.8 2.14 (1.23 , 3.73) 1.15 (0.72 , 1.83) 1.3 (0.93 , 1.82) 1.55 (1.17 , 2.05) 1.87 (1.45 , 2.41) 
 Fatal/non-fatal CVD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
5-23.8 
1 (ref) 0.98 (0.85 , 1.13) 1.05 (0.89 , 1.24) 1.05 (0.84 , 1.32) 1.06 (0.81 , 1.38) 
0.333 
23.9-
28.6 1.14 (0.99 , 1.31) 1.09 (0.95 , 1.25) 0.99 (0.84 , 1.16) 1.1 (0.9 , 1.34) 1.1 (0.89 , 1.36) 
28.7-
33.5 1.12 (0.97 , 1.31) 1.21 (1.05 , 1.39) 1.23 (1.06 , 1.43) 1.1 (0.92 , 1.31) 1.31 (1.1 , 1.56) 
33.6-
39.2 1.43 (1.17 , 1.74) 1.29 (1.08 , 1.53) 1.36 (1.15 , 1.61) 1.28 (1.07 , 1.53) 1.36 (1.15 , 1.61) 
39.3-
69.8 2.38 (1.66 , 3.42) 1.2 (0.89 , 1.63) 1.52 (1.25 , 1.85) 1.48 (1.24 , 1.76) 1.54 (1.31 , 1.81) 
 Fatal CVD 
 HGS Quintile (kg) 
 43-90 35-42 29-34 23-28 0-22 
P value for 
interaction 
5-23.8 
1 (ref) 1.01 (0.7 , 1.46) 1.58 (1.08 , 2.31) 2.55 (1.66 , 3.9) 3.23 (2.06 , 5.08) 
0.004 
23.9-
28.6 0.78 (0.53 , 1.15) 1.3 (0.93 , 1.82) 1.29 (0.89 , 1.87) 1.59 (1.03 , 2.47) 1.91 (1.21 , 3.01) 
28.7-
33.5 1.23 (0.85 , 1.78) 1.24 (0.88 , 1.74) 1.19 (0.82 , 1.73) 1.88 (1.27 , 2.78) 2.3 (1.54 , 3.42) 
33.6-
39.2 1.68 (1.07 , 2.62) 1.73 (1.18 , 2.53) 1.93 (1.32 , 2.82) 2.03 (1.34 , 3.09) 1.88 (1.24 , 2.83) 
39.3-
69.8 2.5 (1.13 , 5.53) 1.2 (0.59 , 2.46) 1.81 (1.1 , 3) 1.78 (1.13 , 2.81) 2.17 (1.45 , 3.27) 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation HGS – hand grip strength 
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 Table S14. Results of MR using continuous genetic risk scores with interaction between HGS and BMI/WHR. 
 
 
Outcome  HR per unit increase in 
HGS at the median 
BMI/WHR 
HR per unit increase in 
BMI/WHR at the median HGS 
Interaction term (HR) Interaction p-
value  
WHR Fatal/Non Fatal CVD 1.03 (0.97 , 1.08) 1.04 (1.00 , 1.07) 0.95 (0.87 , 1.03) 0.205 
CVD Mortality  0.88 (0.75 , 1.02) 0.99 (0.90 , 1.08) 0.92 (0.72 , 1.17) 0.478 
All-cause mortality  0.87 (0.80 , 0.94) 1.02 (0.96 , 1.07) 0.94 (0.82 , 1.07) 0.339 
WHR – waist hip ratio, BMI – body mass index HGS – hand grip strength 
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Figure S1. Estimated association between body composition and fatal/non-fatal CHD and CVD events and cause specific and all-cause 
mortality excluding the first 2, 3 and 4 years of follow u: BMI and Hand Grip Strength. 
 
Associations (adjusted* Hazard Ratios (HRs)) estimated from a Cox Proportional Hazards model, fit separately for those with and without baseline history of CVD. Reference category is 
optimal body composition, i.e. not sarcopenic and not obese. Obesity measured by BMI, and sarcopenia by dominant hand grip strength (HGS). 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and deprivation  
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Figure S2. Estimated association between body composition and fatal/non- CHD events 
and mortality. Obesity measured as BMI > 30, sarcopenia measured as HGS<30kg men and 
<20kg women. 
 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation  
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Figure S3. Estimated association between body composition and fatal/non- CVD events and 
cause specific and all-cause mortality. Obesity measured as BMI>30, sarcopenia measured 
as SMMI in bottom 40%. 
 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation  
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Figure S4. Estimated association between body composition and fatal/non- CVD events and 
cause specific and all-cause mortality. Obesity measured as WHR ≥0.95 in men and ≥0.80 in 
women, sarcopenia measured as HGS<30kg men and <20kg women. 
 
*Adjusted for age, sex, ethnicity and baseline measures of smoking, alcohol consumption, diabetes status physical activity and 
deprivation  
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Figure S5. Relative hazard of fatal/non-fatal CHD and CVD events and cause specific and 
all-cause mortality according to category of body composition (using WHR) as defined by 
genetic scores in a factorial Mendelian randomisation analysis, where weights for the 
genetic score were determined from both external and internal data. 
 
High/Low determined by cutting at the median genetic score. Associations (Hazard Ratios (HRs)) estimated from a Cox 
Proportional Hazards model. P value for the interaction calculated using a likelihood ratio test. 
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Figure S6. Relative hazard of fatal/non-fatal CHD events and mortality according to 
category of body composition as defined by genetic scores estimated from both external in 
internal weights in a factorial Mendelian randomisation analysis. 
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